Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab.
Systemic lupus erythematosus (SLE)-like syndromes and the development of lupus-related autoantibodies are known to occur during treatment with certain medications. Here a case of complete SLE conversion in a patient with rheumatoid arthritis following sequential treatment with infliximab and adalimumab is reported. Potential mechanisms for development of SLE with this treatment regimen are discussed, as well as the need for further exploration into autoimmune phenomenon with the use of immunobiologic agents.
Havel
Jamaiya
J
Texas Tech University School of Medicine, Lubbock, TX, USA.
Aboutalebi
Sina
S
Doughty
Lauren
L
Wirges
Marla
M
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000139:chemically induced* / Q000150:complications; D004247:DNA / Q000276:immunology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications; D008875:Middle Aged; D012867:Skin / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004247:DNA; D000069285:Infliximab; D000068879:Adalimumab